TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana
Brief Summary: Intermittent preventive treatment for malaria in children (IPTc) is a promising new approach to malaria control. Preliminary studies of IPTc in Senegal and Mali indicate that this approach can be very effective. Although the results of these studies suggest that IPTc with sulphadoxine-pyrimethamine (SP) plus artesunate (AS) or SP alone is an efficacious and safe intervention for reducing the burden of malaria and anaemia in children in high transmission areas with short transmission periods, there is no data from areas with long transmission periods. This study aims to evaluate the effectiveness of IPTc in reducing anaemia and malaria in an area with up to 6 months of transmission in Ghana. Two thousand two hundred forty children aged 3-59 months will be randomly allocated to four groups (560 per arm) to receive amodiaquine plus artesunate (AQ+AS), given at two different intervals (monthly or bimonthly), SP or placebo. The children will also be followed to determine if there is any rebound in the incidence of severe malaria and anaemia in the year following IPTc.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A
C: Arm Label: Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control
D: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana
Brief Summary: Intermittent preventive treatment for malaria in children (IPTc) is a promising new approach to malaria control. Preliminary studies of IPTc in Senegal and Mali indicate that this approach can be very effective. Although the results of these studies suggest that IPTc with sulphadoxine-pyrimethamine (SP) plus artesunate (AS) or SP alone is an efficacious and safe intervention for reducing the burden of malaria and anaemia in children in high transmission areas with short transmission periods, there is no data from areas with long transmission periods. This study aims to evaluate the effectiveness of IPTc in reducing anaemia and malaria in an area with up to 6 months of transmission in Ghana. Two thousand two hundred forty children aged 3-59 months will be randomly allocated to four groups (560 per arm) to receive amodiaquine plus artesunate (AQ+AS), given at two different intervals (monthly or bimonthly), SP or placebo. The children will also be followed to determine if there is any rebound in the incidence of severe malaria and anaemia in the year following IPTc.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SP, amodiaquine, piperaquine, dihdroartemisinin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: intermittent preventive treatment | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Du-Cotecxin | Intervention Type: DRUG; Name: SP, amodiaquine, piperaquine, dihdroartemisinin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intermittent preventive treatment; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Du-Cotecxin; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: trimethoprim-sulfamethoxazole (TS; TMP/SMX) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: sulfadoxine-pyrimethamine (SP) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: dihydroartemisinin-piperaquine (DP) | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: trimethoprim-sulfamethoxazole (TS; TMP/SMX); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine (DP); Assigned to Arm(s): 3
C: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
D: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana
Brief Summary: Intermittent preventive treatment for malaria in children (IPTc) is a promising new approach to malaria control. Preliminary studies of IPTc in Senegal and Mali indicate that this approach can be very effective. Although the results of these studies suggest that IPTc with sulphadoxine-pyrimethamine (SP) plus artesunate (AS) or SP alone is an efficacious and safe intervention for reducing the burden of malaria and anaemia in children in high transmission areas with short transmission periods, there is no data from areas with long transmission periods. This study aims to evaluate the effectiveness of IPTc in reducing anaemia and malaria in an area with up to 6 months of transmission in Ghana. Two thousand two hundred forty children aged 3-59 months will be randomly allocated to four groups (560 per arm) to receive amodiaquine plus artesunate (AQ+AS), given at two different intervals (monthly or bimonthly), SP or placebo. The children will also be followed to determine if there is any rebound in the incidence of severe malaria and anaemia in the year following IPTc.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SP, amodiaquine, piperaquine, dihdroartemisinin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: intermittent preventive treatment | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Du-Cotecxin | Intervention Type: DRUG; Name: SP, amodiaquine, piperaquine, dihdroartemisinin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intermittent preventive treatment; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Du-Cotecxin; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sulfadoxine/pyrimethamine and artesunate; Assigned to Arm(s): N/A
D: Arm Label: Combination of Amodiaquine +sulfadoxine-pyrimethamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine + sulfadoxine-pyrimethamine | Arm Label: Dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Sulfadoxine-pyrimethamine alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): Sulfadoxine-pyrimethamine alone | Intervention Type: DRUG; Name: amodiaquine + sulfadoxine-pyrimethamine; Assigned to Arm(s): Combination of Amodiaquine +sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): Dihydroartemisinin-piperaquine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Malaria Among Children In Ghana
Brief Summary: Case management is one of the key strategies for malaria control in most endemic countries. Plasmodium falciparum malaria is becoming resistant to commonly used and cheap antimalarial drugs such as chloroquine, amodiaquine, and sulfadoxine-pyrimethamine (SP). Thus the safety and efficacy of new anti-malarial drugs need to be tested in sites with well-characterised malariometric indices in order to make appropriate treatment policies.

Artemisinin-based combination chemotherapies have been documented to consistently produce faster relief of clinical symptoms and parasite clearance in uncomplicated falciparum malaria than any other currently used antimalarial drugs. So far, artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AR-LM) are the only two registered fixed-dose artemisinin combination chemotherapies produced at industrial scale, with good manufacturing practices and already used in Africa. Several African countries, including Ghana, are therefore introducing either AS-AQ or AR-LM as first-line antimalarials or evaluating the case for such a change. Clearly, a direct comparison of both the safety and efficacy profiles of the two combinations under different epidemiological conditions is urgently needed to guide informed decisions on the most appropriate antimalarial first-line treatment regimen.

This study aims to evaluate the efficacy and safety of artesunate-amodiaquine combination therapy, artemether-lumefantrine, and artesunate-lapdap in an open-labelled, randomised, non-inferiority drug trial.

The study results will inform future decisions on first- and second-line treatments for uncomplicated P. falciparum malaria with respect to efficacy and safety in Ghana.


Options:
A: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A
B: Arm Label: Dihydroartemisin-piperaquine; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisin-piperaquine | Arm Label: Mefloquine + Artesunate (MAS3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine + Artesunate | Intervention Type: DRUG; Name: Dihydroartemisin-piperaquine; Assigned to Arm(s): Dihydroartemisin-piperaquine | Intervention Type: DRUG; Name: Mefloquine + Artesunate; Assigned to Arm(s): Mefloquine + Artesunate (MAS3)
C: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: coartem; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: artesunate-lapdap; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: amodiaquine+artesunate/artemether-lumefantrine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of a Killed, Oral Cholera Vaccine in Indian Subjects in Eastern Kolkata, West Bengal
Brief Summary: The purpose of the study is to confirm the safety and immunogenicity of the oral killed bivalent cholera vaccine in adult and pediatric volunteers in Eastern Kolkata, West Bengal, India.


Options:
A: Arm Label: study group; Type: EXPERIMENTAL; Interventions: Biological: Test Oral Cholera Vaccine | Arm Label: comparator group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Euvichol® | Intervention Type: BIOLOGICAL; Name: Test Oral Cholera Vaccine; Assigned to Arm(s): study group | Intervention Type: BIOLOGICAL; Name: Euvichol®; Assigned to Arm(s): comparator group
B: Arm Label: Shanchol; Type: EXPERIMENTAL; Interventions: Biological: Shanchol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Shanchol; Assigned to Arm(s): Shanchol | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vaccine arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: ShanChol | Arm Label: Vaccine plus hygiene and safe water arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vaccine and behaviour | Arm Label: Non-intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: ShanChol; Assigned to Arm(s): Vaccine arm | Intervention Type: BEHAVIORAL; Name: Vaccine and behaviour; Assigned to Arm(s): Vaccine plus hygiene and safe water arm
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli | Intervention Type: BIOLOGICAL; Name: killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of a Killed, Oral Cholera Vaccine in Indian Subjects in Eastern Kolkata, West Bengal
Brief Summary: The purpose of the study is to confirm the safety and immunogenicity of the oral killed bivalent cholera vaccine in adult and pediatric volunteers in Eastern Kolkata, West Bengal, India.


Options:
A: Arm Label: Placebo injection; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Injection | Arm Label: TA-CD Vaccination; Type: EXPERIMENTAL; Interventions: Drug: TA-CD Vaccination | Intervention Type: DRUG; Name: TA-CD Vaccination; Assigned to Arm(s): TA-CD Vaccination | Intervention Type: OTHER; Name: Placebo Injection; Assigned to Arm(s): Placebo injection
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Killed bivalent whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli Placebo | Intervention Type: BIOLOGICAL; Name: Killed bivalent whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: bivalent killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: bivalent killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli | Intervention Type: BIOLOGICAL; Name: killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Lateral Epicondylitis With Botulinum Toxin: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether Botulinum A toxin is effective in the treatment of tennis elbow (lateral epicondylitis).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fremanezumab 675 mg/placebo/placebo; Type: EXPERIMENTAL; Interventions: Drug: Fremanezumab, Drug: Placebo | Arm Label: Fremanezumab 675/225/225 mg; Type: EXPERIMENTAL; Interventions: Drug: Fremanezumab | Intervention Type: DRUG; Name: Fremanezumab; Assigned to Arm(s): Fremanezumab 675 mg/placebo/placebo, Fremanezumab 675/225/225 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fremanezumab 675 mg/placebo/placebo, Placebo
B: Intervention Type: DRUG; Name: Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Botulinum toxin A injection or normal saline; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Erenumab 70 mg QM; Type: EXPERIMENTAL; Interventions: Drug: Erenumab | Arm Label: Erenumab 140 mg QM; Type: EXPERIMENTAL; Interventions: Drug: Erenumab | Intervention Type: DRUG; Name: Erenumab; Assigned to Arm(s): Erenumab 140 mg QM, Erenumab 70 mg QM | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cost Effectiveness of Two Different Strategies to Implement the NVOG Guideline Programme on Subfertility
Brief Summary: The purpose of this study is to compare two different strategies to implement the existing Guideline programme on Subfertility, as issued by the Dutch Society of Obstetrics and Gynaecology (NVOG). Therefore, an innovative patient-directed strategy will be compared to a control strategy and effectiveness, costs and feasibility of both strategies will be assessed.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1
B: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A
C: Arm Label: minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: professional audit and feedback (guideline adherence) | Arm Label: maximal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: patient education, Behavioral: professional audit and feedback (guideline adherence), Behavioral: professional education (communication/shared decision making), Other: information tools | Intervention Type: BEHAVIORAL; Name: patient education; Assigned to Arm(s): maximal intervention | Intervention Type: BEHAVIORAL; Name: professional audit and feedback (guideline adherence); Assigned to Arm(s): maximal intervention, minimal intervention | Intervention Type: BEHAVIORAL; Name: professional education (communication/shared decision making); Assigned to Arm(s): maximal intervention | Intervention Type: OTHER; Name: information tools; Assigned to Arm(s): maximal intervention
D: Intervention Type: BEHAVIORAL; Name: Quality improvement strategies; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Scandinavian Candesartan Acute Stroke Trial
Brief Summary: The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure.

Hypothesis:

AT1 receptor blockade with candesartan in acute stroke will:

1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo.
2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo


Options:
A: Intervention Type: DRUG; Name: Labetalol Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metoprolol tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Hydralazine Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Glycerol Trinitrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Phentolamine mesylate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nicardipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Urapidil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Esmolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Enalaprilat; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nitroprusside; Assigned to Arm(s): N/A
B: Arm Label: Candesartan Cilexetil; Type: EXPERIMENTAL; Interventions: Drug: Candesartan Cilexetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Candesartan Cilexetil; Assigned to Arm(s): Candesartan Cilexetil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intensive BP lowering; Type: OTHER; Interventions: Other: Blood pressure management policies | Arm Label: Guideline recommended BP lowering; Type: OTHER; Interventions: Other: Blood pressure management policies | Intervention Type: OTHER; Name: Blood pressure management policies; Assigned to Arm(s): Guideline recommended BP lowering, Intensive BP lowering
D: Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: Lisinopril | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Scandinavian Candesartan Acute Stroke Trial
Brief Summary: The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure.

Hypothesis:

AT1 receptor blockade with candesartan in acute stroke will:

1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo.
2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo


Options:
A: Arm Label: Standard SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Arm Label: Intensive SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Intervention Type: DRUG; Name: Intravenous nicardipine hydrochloride; Assigned to Arm(s): Intensive SBP Reduction Arm, Standard SBP Reduction Arm
B: Arm Label: Clazosentan 5 mg/h; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan 5 m/h | Arm Label: Clazosentan 15 mg/h; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan 15 mg/h | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Clazosentan 5 m/h; Assigned to Arm(s): Clazosentan 5 mg/h | Intervention Type: DRUG; Name: Clazosentan 15 mg/h; Assigned to Arm(s): Clazosentan 15 mg/h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intensive BP lowering; Type: OTHER; Interventions: Other: Blood pressure management policies | Arm Label: Guideline recommended BP lowering; Type: OTHER; Interventions: Other: Blood pressure management policies | Intervention Type: OTHER; Name: Blood pressure management policies; Assigned to Arm(s): Guideline recommended BP lowering, Intensive BP lowering
D: Arm Label: Candesartan Cilexetil; Type: EXPERIMENTAL; Interventions: Drug: Candesartan Cilexetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Candesartan Cilexetil; Assigned to Arm(s): Candesartan Cilexetil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D